
Ranbaxy Laboratories has started exports of a copycat version of blockbuster cholesterol drug Lipitor from a new facility in India that has been approved by the US Food and Drug Administration. The company, majority owned by Japan’s Daiichi Sankyo, has been selling the generic version in the United States since last Dec.1 from its facility in America but exports to the United States from its plants in India were banned in 2009 over disputes related to compliance issues. Ranbaxy, India’s biggest drugmaker by sales, said on Monday the US authorities approved the generic dosages manufactured at the Punjab facility in northern India in the first quarter of this year. “Our new facility will cater to the US and other geographies, improving access to medicines, in these regions,” Chief Executive Arun Sawhney said in a statement. Ranbaxy started selling the generic version of Lipitor in four European markets -Germany, Italy, the Netherlands and Sweden -from its US-based Ohm Laboratories Inc early this year. Analysts said Ranbaxy would have to boost sales for the operation to become cost effective. “We need to check on the volumes that are shipped from India,” a pharmaceuticals analyst in Mumbai said.
GMT 17:56 2018 Wednesday ,17 January
Ericsson to write down 1.4 billion euros in fourth quarterGMT 19:16 2018 Saturday ,13 January
China shuts Marriott website over Tibet error, scolds other firmsGMT 17:31 2018 Thursday ,11 January
UK group bids for Europe's biggest aluminium smelterGMT 17:24 2018 Thursday ,11 January
UK supermarket Sainsbury's lifts outlook after bumper ChristmasGMT 17:52 2018 Tuesday ,09 January
H&M removes 'black boy' ad after racism accusationGMT 19:38 2018 Wednesday ,03 January
Petrobras pay $2.95bn to settle US class action on corruptionGMT 13:49 2018 Wednesday ,03 January
China’s Ant Financial drops $1.2 billion MoneyGram deal as US approval failsGMT 17:47 2017 Sunday ,31 December
BA owner to buy bankrupt Austrian airline Niki
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor